Zevra Therapeutics, Inc.
NASDAQ:ZVRABiotechnology
+$0.31 today
- Market cap
- $552.20M
- Beta
- 0.89
- P/E (TTM)
- 6.1
- EPS (TTM)
- $2.13
Volume 0.62M
Average 1.43M
ZVRA Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
Zevra Therapeutics, Inc.NASDAQ: ZVRA
Net Receivables · Q1 FY2026 · quarter ended Mar 2026
Net receivables rises 75.1% from a year ago
Net receivables stood at $22.1M at the end of Q1 FY2026, up 75.1% from a year earlier and down 5.0% from the prior quarter. Over 3 fiscal years it compounded at +41.0% a year.
Context
- Net receivables amounted to 7.9% of total assets at the end of Q1 FY2026, up 0.6 pp from a year earlier.
- Net receivables increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net receivables keeps rising in the next quarterly balance sheet after a +75.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 23.26M USD
- Year-over-year change
- +121.3%
- 4-year CAGR
- +97.5%
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 23.26M | +121.3% |
| FY2024 | 2024-12-31 | 10.51M | -39.5% |
| FY2023 | 2023-12-31 | 17.38M | +109.4% |
| FY2022 | 2022-12-31 | 8.3M | +443.1% |
| FY2021 | 2021-12-31 | 1.53M | — |
Net Receivables vs competitors
How ZVRA compares with its peers on the latest reported figures
- ZVRA's Mar 2026 net receivables of $22.1M is the 5th highest of the 11 companies compared; the peer median is $584.5K.
- Its year-over-year change of +75.1% is the highest of 6, against a peer median of +31.5%.
- Net receivables amounts to 7.9% of total assets for ZVRA, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $957.3M | +31.5% | +25.2% | 17.0% | |
| Sep 2026 | $873.7M | +14.3% | +8.4% | 7.3% | |
| Sep 2026 | $459.09M | +29.3% | +4.0% | 10.4% | |
| Jun 2026 | $211.66M | +50.3% | +4.3% | 14.8% | |
| Mar 2026 | $22.1M | +75.1% | +41.0% | 7.9% | |
| Sep 2026 | $1.17M | +44.0% | +11.6% | 0.1% | |
| Sep 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | +143.2% | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $0 | — | — | 0.0% |
| Peer median (excluding ZVRA) | $584.5K | +31.5% | +10.0% | 0.0% | |
Competitors are the stored peer set for ZVRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 112.35M | 65.47M | 43.05M | 33.79M | 62.41M |
| Short-term Investments | 0 | 17.38M | 24.69M | 35.71M | 128.6M |
| Net Receivables | 1.53M | 8.3M | 17.38M | 10.51M | 23.26M |
| Inventory | 0 | 0 | 24.08M | 1.97M | 1.74M |
| Other Current Assets | 252K | 1.11M | (23.43M) | 3.02M | 7M |
| Total Current Assets | 115.06M | 92.83M | 86.94M | 86.03M | 223.01M |
| Property, Plant & Equipment (Net) | 2.03M | 1.78M | 1.53M | 1.01M | 1.7M |
| Goodwill | 0 | 0 | 4.7M | 4.7M | 4.7M |
| Intangible Assets | 0 | 0 | 69.23M | 68.99M | 6.42M |
| Long-term Investments | 15.42M | 20M | 0 | 6.01M | 47.88M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 438K | 724K | 9.94M | 11.38M | 1.02M |
| Total Non-current Assets | 17.89M | 22.51M | 85.39M | 92.1M | 61.72M |
| Total Assets | 132.94M | 115.34M | 172.33M | 178.13M | 284.73M |
| Account Payables | 516K | 3.61M | 13.99M | 13.08M | 2.48M |
| Short-term Debt | 0 | 4.66M | 37.7M | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 14.43M | 13.71M |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 821K | 719K | 10.82M | 3.2M | 22.67M |
| Total Current Liabilities | 4.23M | 12.02M | 73.72M | 34.07M | 39.28M |
| Long-term Debt | 0 | 12.8M | 5.07M | 59.5M | 61.93M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 355K | 14.55M | 31.22M | 44.52M | 28.01M |
| Total Non-current Liabilities | 1.59M | 28.2M | 36.74M | 104.4M | 90.8M |
| Total Liabilities | 5.82M | 40.22M | 110.46M | 138.46M | 130.07M |
| Common Stock | 4K | 3K | 4K | 5K | 6K |
| Retained Earnings | (267.03M) | (353.73M) | (399.78M) | (505.29M) | (422.06M) |
| Accumulated OCI | (0) | 113K | (43K) | 631K | (764K) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 127.12M | 75.12M | 61.86M | 39.67M | 154.66M |
| Total Debt | 1.61M | 18.78M | 43.77M | 60.3M | 63.21M |
| Net Debt | (110.74M) | (46.69M) | 716K | 26.51M | 800K |
Zevra Therapeutics, Inc.
NASDAQ:ZVRA
Intrinsic Alpha fair value
Locked
Current Price
$9.28
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.